ANÁLOGOS DE GLP-1 NA DOENÇA DE PARKINSON: UMA REVISÃO

Authors

  • Laís Macêdo Maciel Universidade Federal de Pernambuco
  • João Gabriel Falcão de Moraes
  • Ingrid Prata Mendonça
  • Caio Victor Barros Gonçalves da Silva
  • Karolliny Barbosa de Araújo
  • Igor Henrique Rodrigues de Paiva
  • Ellen Kosminsky
  • Camilla de Andrade Tenorio Cavalcanti
  • Maria Lavinya Arruda da Rocha
  • Isvânia Maria Serafim da Silva Lopes

DOI:

https://doi.org/10.18616/inova.v14i5.8576

Abstract

Parkinson's Disease (PD) is a neurodegenerative disorder that affects mobility and cognitive function, originating from the loss of dopamine-producing neurons. Understanding PD and developing new therapies are challenging due to the complexity of the involved neuronal mechanisms. The aim of this review was to investigate the efficacy of GLP-1 analogs as a potential treatment for PD, exploring their neuroprotective effects and the ability to improve motor and non-motor symptoms. A systematic review was conducted in the PubMed, Scopus, Lilacs, and Web of Science databases, using the descriptors "Parkinson's Disease" and "GLP 1 Receptor". Studies that addressed the use of GLP-1 analogs in preclinical and clinical models of PD were selected. The results showed that GLP-1 analogs possess antioxidant, anti-inflammatory, and neuroprotective properties in PD models, suggesting therapeutic potential. Preliminary clinical studies indicate an improvement in PD symptoms, but more randomized clinical trials are needed to confirm these results. Therefore, GLP-1 analogs emerge as a promising class of drugs for the treatment of PD, with the possibility of offering benefits beyond glycemic control, including neuroprotection and improvement of motor and non-motor symptoms.

Downloads

Download data is not yet available.

Published

2024-06-28